DATA - The Buzz Show: Adicet Bio Inc. (NASDAQ: ACET) Interim Clinical Data from Dose Escalation Phase 1 Study

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adicet Bio, Inc. Announces Positive Interim Clinical Data from Dose Escalation Phase 1 Study ”

Adicet Bio, Inc. (NASDAQ: ACET) surged over 38% in premarket trading after the company announced positive interim data from its dose escalation Phase 1 study.

Evaluating the safety and tolerability of ADI-001, an investigational therapy targeting CD20 for the potential treatment of B-cell Non-Hodgkin’s Lymphoma, the study showed that ADI-001 infusions were generally well-tolerated.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

For more information, please visit: Adicet Bio, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Adicet Bio, Inc. (NASDAQ: ACET) Interim Clinical Data from Dose Escalation Phase 1 Study first appeared on Financial Buzz .

For further details see: